Lucky Seven Chief Takes on World Marathon Challenge for Teenage Cancer Trust


Chris Jonns, Lucky Seven’s chief, is participating in the World Marathon Challenge in aid of Teenage Cancer Trust. 
Teenage Cancer Trust is the only UK charity which provides specialist care and support to teenagers and young adults diagnosed with cancer. Starting off on the 29th January, Chris will be tackling 7 marathons in 7 continents in 7 days. 
The mammoth trial is a physical, psychological and logistical challenge with competitors running standard 26-mile marathons in Antarctica, Africa, Australia, Asia, Europe, South America and North America within 168 hours or 7 days. A feat of sheer endurance and determination, the World Marathon Challenge is an unparalleled adventure. 

Throughout his 183.5 mile endeavour in Novo, Cape Town, Perth, Dubai, Madrid, Santiago and Miami, Chris will be sporting Lucky Seven’s iconic ‘777’ caps. Bolstering Chris’s support of Teenage Cancer Trust, Lucky Seven will be donating all profits from the sales of the ‘777’ collection to this extraordinary charity. From providing specialist cancer units within NHS hospitals, to age-appropriate nursing and support for young people in local hospitals and at home, to education and awareness presentations in schools, the Teenage Cancer Trust provides an admirable service of care for young people facing cancer. 
Follow Chris’s adventure and support a vital UK charity this January with Lucky Seven and its ‘777’ collection.




About Chris Jonns

Chris Jonns has been a serial entrepreneur and investor for the last fifteen years developing a diverse portfolio. Whilst born in the UK, Chris has lived in New York for the last 20 years and provided advice and guidance to many entrepreneurs both sides of the Atlantic. He is the founder of Rewired, the group that owns Lucky Seven, along with being at the core of establishing all Rewired’s current portfolio of brands. Chris was also one of the founding partners of leading brand Pretty Green. As a serial investor, one of his most significantinvestments is in Biosceptre, a UK headquartered biotech developing next-generation cancer therapeutics.

Click HERE to view the collection

Click HERE to donate via JustGiving (UK only)

Click HERE to donate via JustGiving (USA only)

January 22, 2019